Polski   English  

Biosensors

History of Firsts in Interventional Cardiology

Biosensors have demonstrated and proven  commitment to innovation in interventional cardiology as they were the:
  • * First cardiology device company to develop a proprietary drug specifically designed for coronary stent use — BA9™ (Biolimus A9™) the compound is proprietary to Biosensors and is not licensed from a pharmaceutical company;
* First company to successfully develop and launch an abluminal biodegradable polymer DES with a coating absorbed after 6 to 9 months*;

* First company to sponsor a randomized head-to-head comparison against a sirolimus eluting stent in an all-comers setting;

* First company to prove non-inferiority on a clinical endpoint against JnJ  Cordis Cypher® Select™1;

* First company to launch a BA9™- eluting dedicated bifurcation stent.

* First company to sponsor a randomized head-to-head, double-blinded comparison of DES and BMS in patients considered at high-risk of bleeding